Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan

Nephrology Dialysis Transplantation

Volumn 24, Issue 6, 2009, Pages 1876-1883

  Guo, Li Li ^a   Pan, Yu ^b   Jin, Hui Min ^b  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adiponectin; Angiotensin II type 1 receptor (ARB); Diabetic nephropathy; Insulin resistance; Losartan

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; TREATMENT DURATION;

ADIPONECTIN; ADULT; AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; PROTEINURIA; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 67651097807     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn770     Document Type: Article

References (37)

1. Brenner BM, Cooper ME, de Zeeuw D et al. For the RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
2. Olsen MH, Fossum E, Hoieggen A et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23: 891-898
3. Jin HM, Pan Y. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. Nephrol Dial Transplant 2007; 22: 1943-1949
4. Ryan AS, Berman DM, Nicklas BJ et al. Plasma adiponectin and leptin levels, body composition, and glucose utilization in adult women with wide ranges of age and obesity. Diabetes Care 2003; 26: 2383-2388
5. Zoccali C, Mallamaci F, Panuccio V et al. Adiponectin is markedly increased in patients with nephritic syndrome and is related to metabolic risk factors. Kidney Int 2003; 63(Suppl 84): S98-S102
6. Schalkwijk CG, Chaturvedi N, Schram MT et al. and the EURODIAB Prospective Complications Study Group. Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 2006; 91: 129-135
7. Saraheimo M, Forsblom C, Fagerudd J et al. on behalf of the FinnDiane Study Group. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410-1414
8. Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Diabetes Care 2007; 30: 239-244
9. Jorsal A, Tarnow L, Frystyk J et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008; 74: 649-654
10. Furuhashi M, Ura N, Higashiura K et al. Blockade of the renin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 2003; 42: 76-81
11. Tomiyama H, Motobe K, Zaydun G et al. Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens 2005; 18: 178-182
12. Nomura S, Shouzu A, Omoto S et al. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385-392
13. Usui I, Fujisaka S, Yamazaki K et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 210-214
14. Bonora E, Targher G, Alberiche M et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63
15. Looker HC, Krakoff J, Funahashi T et al. Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 4010-4017
16. Guebre-Egziabher F, Bernhard J, Funahashi T et al. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 2005; 20: 129-134
17. Rodríguez A, Catalán V, Becerril S et al. Impaired adiponectin-AMPK signaling in insulin-sensitive tissues of hypertensive rats. Life Sci 2008; 83: 540-549
18. Perseghin G, Lattuada G, Danna M et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 2003; 285: E1174-E1181
19. Sharma K, RamachandraRao S, Qiu G et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118: 1645-1656
20. Groop PH, Forsblom C, Thomas MC. Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 2005; 1: 100-110
21. Yilmaz MI, Saglam M, Carrero JJ et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965
22. Kurata A, Nishizawa H, Kihara S et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006; 70: 1717-1724
23. Furuya R, Odamaki M, Kumagai H et al. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif 2006; 24: 445-450
24. Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007; 24: 146-153
25. Koh KK, Quon MJ, Han SH et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110: 3687-3693
26. Park H, Hasegawa G, Obayashi H et al. Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. Clin Chim Acta 2006; 374: 129-134
27. Aksnes TA, Seljeflot I, Torjesen PA et al. Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity. Metabolism 2007; 56: 1470-1477
28. de Vinuesa SG, Goicoechea M, Kanter J et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: S206-S212
29. Wang Y, Xu A, Knight C et al. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. JBiolChem 2002; 277: 19521-19529
30. Leth H, Andersen KK, Frystyk J et al. Elevated levels of high-molecular-weight adiponectin in type 1 diabetes. J Clin Endocrinol Metab 2008; 93: 3186-3191
31. Kollerits B, Fliser D, Heid IM et al. Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int 2007; 71: 1279-1286
32. Bandyopadhyay GK, Yu JG, Ofrecio J et al. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis: thiazolidinedione treatment reverses these defects. Diabetes 2006; 55: 2277-2285
33. Kraegen E, Saha A, Preston E et al. Increased malonyl-CoA and diacylglycerol content and reduced AMPK activity accompany insulin resistance induced by glucose infusion in muscle and liver of rats. Am J Physiol Endocrinol Metab 2006; 290: E471-E479
34. Menon V, Li L, Wang X et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006; 17: 2599-2606
35. Qi Y, Takahashi N, Hileman SM et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529
36. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16600 patients in primary care. Curr Med Res Opin 2004; 10: 1625-1631
37. Lozano JV, Llisterri JL, Aznar J et al. on behalf of a Spanish Working Group. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001; 16: 85-89